Compare · ATAI vs MRK
ATAI vs MRK
Side-by-side comparison of AtaiBeckley Inc. (ATAI) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATAI and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK carries a market cap of $353.44B.
- MRK has hit the wire 22 times in the past 4 weeks while ATAI has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- AtaiBeckley Inc.
- Merck & Company Inc.
- Price
- -
- -
- Market cap
- -
- $353.44B
- 1M return
- -
- -6.17%
- 1Y return
- -
- +44.22%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2008
- News (4w)
- 0
- 22
- Recent ratings
- 25
- 25
AtaiBeckley Inc.
Atai Life Sciences N.V. focuses on operating as a holding company for ATAI Life Sciences AG that operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01 is a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest ATAI
- SEC Form 15-12G filed by AtaiBeckley Inc.
- SEC Form S-8 POS filed by AtaiBeckley Inc.
- SEC Form S-8 POS filed by AtaiBeckley Inc.
- SEC Form S-8 POS filed by AtaiBeckley Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by AtaiBeckley Inc.
- Chief Medical Officer Craig Kevin James returned 8,437 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax
- SEC Form 4 filed by Chief Operating Officer Kochendoerfer Gerd (for withholding tax)
- Officer Barrett Christopher Ryan Cave returned 155,066 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding tax)
- Chief Scientific Officer Short Glenn Frank returned 42,333 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Hoffman John Francis to satisfy tax liability
Latest MRK
- Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director
- Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib
- Merck Announces First-Quarter 2027 Dividend
- EVP&Pres, Merck Animal Heallth Deluca Richard R. exercised 58,185 shares at a strike of $77.62 and sold $8,611,875 worth of shares (58,185 units at $148.01), decreasing direct ownership by 0.00% to 112,955 units (SEC Form 4)
- SEC Form 13F-HR filed by Merck & Company Inc.
- Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
- Merck to Participate in the Jefferies Global Healthcare Conference in London
- Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
- FDA Approval for WELIREG issued to MERCK SHARP DOHME
- SEC Form 10-Q filed by Merck & Company Inc.